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THE MORBIDITY arising from the chronic use of 
.1. anti-rejection medications is an incentive to establish 
the lowest posSIble level of immunosuppression necessary 
to maintain stable graft function. The finding that freedom 
from immunosuppression was sporadically possible in long-
surviving recipients of liver allografts and the concurrent 
evidence that chimerism was uniformly demonstrable in 
such tolerant patients! have led to a prospective trial of 
complete drug weaning. In our initial experience, it was 
shown that significant reductions in medication or their 
discontinuance could be safely accomplished in liver,: and 
even in a handful of living-related kidney recipients who 
have been drug free for as long as 30 years.3 However, the 
danger of consequent allograft rejection has not been 
completely assessed and guidelines for judicious weaning 
need to be clarified. We present here further follow-up on 
our previously reported weaning trial in liver allograft 
recipients2 and results from additiona.l patients subse-
quently entered. 
METHODS 
Case Material 
We report 95 patients whose weaning was begun between June 
1992 and April 1996 after meeting the following criteria: (1) >5 
years post-transplantation: (2) >2 years without a documented 
rejection episode: (3) evidence of medical compliance: (4) avail-
ability of cooperative local physician for follow up; (5) absence of 
acute or chronic rejection on baseline liver biopsy; and (6) exclu-
sion of other diagnoses such as vascular or biliary tract complica-
tions or recurrence of original disease. Thirty-one patients were 
under age 20 at the time of weaning and 64 were between 21 and 
68 years of age. 
Original recipient diagnoses included viral hepatitis (n = 13), 
biliary atresia (n = 25). autoimmune hepatitis (n = 4), primary 
sclerosing cholangitis or primary biliary cirrhosis (n = 16), hepa-
toma (n = 4), and a miscellaneous group (n = 33) that included 
alcoholic cirrhosis, cryptogenic cirrhosis, Budd-Chiari, toxic or 
secondary biliary cirrhosis. Wilson disease. hemochromatosis, a-I 
anti-trypsin deficiency. polycystic liver disease. and cystic fibrosis. 
All were recipients of isolated liver allografts. except for 2 patients 
who also received a simultaneous kidncy graft from their liver 
donor. 
Baseline Immunosuppression 
Immunosuppression at the stan of weaning conslstcd of azathio-
prine (AZA)/prcdnisonc (PRED) in 13 cases. cyciosporinc (CvA)/ 
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PRED in 32, Cya/AZA/PRED in 24, CyAiAZA in 4, CyA alone in 
11, tacrolimus (TAC) in 8, TACIPRED in 1, and TAC/AZA in 2 . 
Complications of Immunosuppression 
Complications of long-term immunosuppression present at the 
initiation of weaning included hypertension (n = 32), renal insuf-
ficiency (n = 27), skin lesions or malignancy (n = 12), neurologic 
symptoms or findings (n = 4), infection (n = 6), steroid-related 
complications (n = 9) such as obesity, growth failure, and bone 
disease, and diabetes (n = 9). Thirty-seven patients had multiple 
complications attributable to their immunosuppression. 
Weaning Protocol 
At the beginning of the prospective triaV AZ.A was the first drug 
weaned when it was part of triple drug therapy. Before complete 
PRED weaning, corticotropin stimulation testing was done to 
detect adrenal insufficiency. The baseline immunosuppressive 
agent CyA, AZA, or TAC (Prograf) was then withdrawn by 25% 
increments at 1 to 2 month intervals as long as hepatocellular 
enzyme results remained stable. Beginning in 1994, the rate of 
weaning was slowed and the order of drug discontinuance altered 
with emphasis on primary reduction of maintenance CyA or TAC 
with very slow subsequent attention of PRED and AZA (if this was 
part of the regimen). 
Monitoring. Liver injury tests consisting of AST, ALT, GGTP. 
and serum bilirubin were monitored weekly after changes in drug 
dosage. A liver biopsy was obtained if liver function abnormalities 
developed. Treatment for documented cellular rejection consisted 
of return to the medications preceding the last dose reduction with 
or without pulse steroid therapy. A switch to tacrolimus therapy in 
patients previously on other baseline therapy was reserved for 
moderate or severe ACR or evidence of developing chronic 
rejection. 
RESULTS 
Graft Loss and Patient Survival 
Two patients died during the study period from non-liver 
allograft related causes. both with normal liver function. 
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Table 1. Prospective Weaning Trial Results (n = 95) 
Weaning in 
Ot! Drugs Progress Rejection Weaning Intenrupted' 
Number of patients (%) 18 (19) 37(39) 28(29) 12 (13) 
Years from transplant to 
weaning start 
mean::!: so- 8.3 ::!: 5.4 8.1 ::!: 4.2 8.9:!: 3.4 8.5::!: 6.0 
median (range) 7.6 (1.8-21.6) 7.8 (1.7-21.3) 8.7 (3.1-19.6) 6.7 (1.8-25.0) 
Time from weaning to off, :Kc··~i;1;y·: Not Applicable ... : ... , ::J' 
rajectlon or weaning ·_~t ~:I~~I: ,-, 
Interruption (mo) : ~Kg; 'L: .'. . 
mean ± SO 5.9 ± 5.9 13.2 ± 11.6 12.0 ± 8.3 
median (range) 0.28 (0-31.7) 9.4 (0.4-42.5) 9.5 (2.6-27.2) 
Follow-up (mo) 
mean ± sot 34.5 ± 11.2 33.6:!: 18.1 22.8 ± 14.4 
median (range) 35.5 (10.1-57.2) 19.6 (1.1-66.2) 25.3 (0.2-42.4) 
'Because of noncompliance (n = 8), recurrent disease (PBC, n = 2), pregnancy (n = 1), and renal failure requiring renal transplant (n = 1). 
"p = .901 (ANOVA). 
t As of 5/6/96 or patient death. 
The first who was still weaning died from septic pulmonary 
complications of cystic fibrosis. The second patient, who 
had been returned to baseline immunosuppression follow-
ing an easily controlled mild acute cellular rejection, died 
from a pulmonary embolus following complications from a 
severe toe nail infection. It is noteworthy that these deaths 
were directly or indirectly attributable to the morbidity of 
chronic immunosuppression which the weaning protocol 
was designed to ameliorate. There were no other graft 
losses. 
Status of Prospective Weaning 
Table 1 depicts the current status of the 95 patients 
prospectively weaned. The status of weaning is as follows. 
Complete. Eighteen (19%) of the 95 patients in the 
prospective cohort have been drug free for 0.S4 to 4.S years. 
Seven of these recipients already were on low levels of 
immunosuppression at the first visit to the weaning clinic 
and had drugs stopped at that time. The 11 others were 
weaned over a mean period of 6.6 months. 
In Progress. Currently 37 patients are in the uninter-
rupted process of drug weaning. The mean percentage 
decrease in drug dosing from baseline in these patients is 
13% of AZA dose. 30% of CyA dose. 14% of prednisone 
dose, and 44% of the tacrolimus dose. 
lntemlpted by Rejectioll. Eighteen patients had weaning 
interrupted because of histopathologically confirmed rejec-
tion. 7 more because this diagnosis was suspected although 
not proved. and 3 hecause of suspicion of incipient chronic 
rejection. 
Withdrawal From Protocol. Twelve patients were with-
drawn from the protocol due to noncompliance (n = ~FK 
pregnancv (n = I). renal failure requiring kidnev transplan-
tation (n = I). and recurrent disease (PBC) (11 = 2). The i\ 
cxcluded bccause of noncompliance were left at whatever 
level of treatment had been reached at the time the decision 
to stop weaning was made. All i\ arc well. 
Results by Immunosuppression Regimens 
There was no significant difference in the prospective trial 
in the rate of success when the baseline immunosuppressant 
was tacrolimus or azathioprine. However, there was a 
difference between these groups and all of the cyclosporine-
based regimens (P < .003). Azathioprine/prednisone-based 
patients were more likely to be off drugs at one year as 
compared to cyclosporine-based patients (P = .0007, log 
rank). Tacrolimus-based patients had a similar advantage 
(P = .0031, log rank). 
Impact on Preexisting Complications 
The drug-free patients (n = IS) did not have a significant 
change in renal function or an improvement in hyperten-
sion. The most common benefits were resolution of gingival 
hyperplasia in 2 children. resolution of infections in 3. 
resolved Iymphoproliferative disorders in 3, and relief of 
neuro-psychiatric complaints in 2. 
Six drug free patients completed a short-form health 
survey4 assessing 8 areas of patient well-being including 
physical function. general health. emotional health. and 
social functioning. When compared with age-matched 
transplant recipients on immunosuppression more than 5 
years after transplant. survey scores were significantly 
higher in this small group of patients off drugs (K. 
Ringeride. personal communication). 
Allograft Related Adverse Events 
Significant hepatocellular enzyme elevations (AST. ALT. 
GGTP) occurred in ~~ prospectively weaned patients dur-
ing the study period. followed hv liver biopsy in 37. The 
biopsy findings were: ~lcute cellular rejection (n = IS). 
chronic duct injury (11 = -') not severe enough to meet 
criteria of chronic rejection (see helowl. hepatitis (n = -'). 
normal pathology (n = 7). cyidence of biliary tract obstruc-
tion (n = -,). non-srecllic portal inflammation (n = :; l. and 
steatosis (n = I). 
", 
-. 
--------------------------------
1176 MAZARIEGOS, REYES, MARINO ET AL 
Table 2. Current Status After Two Additional Years of 19 Previously Reported Patients2 Who Had Enzyme Elevations During 
Weaning Without a Definitive Explanation 
Biopsy at First Enzyme 
on Diagnosis Elevation Follow-up Therapy (interval) Currant Status' 
2134 SA Normal Normal Of drugs 
0886 NANB Hepatitis Lobular reactivity Hepatitis (23 mol Weaning 
0512 PBC Lobular reactivity NA On drugs 
0440 A-1-A None NA On drugs 
1308 Hepatitis C Lobular reactivity Moderate ACR (23 months) On drugs 
0202 WIIeon's disease BIle duct obatruction NA 01 drugs 
0235 PBC None NA W8ing 
14 SA RegeneratIve hyperplasia Early duct Injury (19 months) On drugs 
0042 WIlson's disease None NA Of drugs 
0105 Cryptogenic Lobular reactivity NA Of drugs 
1484 Alcoholic Cirrhosis None ACR(4 mo) Of drugs 
0289 NASA Hepatitis None Hepatitis (6 mol Weaning 
331 PBC Lobular reactivity Chronic duct Injury (8 mol On drugs 
476 Cystic fibrosis Normal NA Died during weaning" 
1215 Halothane hepatitis None NA Of study; pregnancy 
314 SA None Hepatitis (6 mol Weaning 
474 Hepatitis B Hepatitis NA On drugs 
518 PBC Lobular reactivity Recurrent PBC (15 mol On drugs 
1182 NANB Hepatitis Hepatitis NA On drugs 
'Eighteen surviving patients ant all clinically well with good or completely normal liver function. 
*"Pulmonary infection associated with cystic fibrosis. 
Abbrevietions: NA = not available; SA = biliary atresia; PBC = Primary biliary cirrhosis; A1-A = A1pha-1 Anti-Trypsin deficiency. 
Acute Cellular Rejection (n = 18). The biopsy proved 
acute cellular rejections documented in 18 patients oc-
curred at a mean time of 13.2 months after weaning was 
started. The characteristic mononuclear cell infiltrate was 
mild in most cases as was reflected in the fact that only one 
recipient had an increase in serum bilirubin. There was no 
significant difference in the laboratory trends of AST/ALT/ 
GGTP in the proved rejection group (n = 18) versus the 
weaning (n = 37) group. 
Treatment consisted of pulse steroids and resumption of 
the baseline medication schedules in 15 patients, with 
prompt return of hepatocellular function to normal. The 
other 3 patients, all on CyA-based regimens, were con-
verted to tacrolimus therapy because of a moderate acute 
rejection on biopsy, including the one who developed 
jaundice 29 months after all drugs were stopped. OKT3 was 
not given to any of the 95 patients in the trial. One patient 
developed herpes stomatitis following treatment for rejec-
tion. Otherwise there were no infectious complications 
following resumption of anti-rejection therapy. 
Unconfinned Acute Cellular Rejection (II = 7). This group 
included 4 of the 7 patients who did not undergo biopsy 
before intensifying immunosuppression. and 3 whose cur-
rent biopsy revealed only early chronic duct injury that was 
unchanged from findings in the baseline hiopsies (before 
weaning). Because there was normalization of liver injury 
tests after thc increase of immunosuppression. these 7 cases 
were arbitrarily included in the acute rejection category. 
Suspected Chrollic Rejectioll (II = 3). This diagnosis. 
which is defined as greater than 501''c bile duct loss or 
ohliterative :1rleriopathy" was not made in any of the 1)5 
patients. However, allografts developed de novo his-
topathologic evidence during weaning of low-grade bile 
duct injury, prompting restoration of the previous level of 
immunosuppression in 2 cases, and conversion to tacroli-
mus in the third. 
Vual Hepatitis (n = 3). Two patients developed biopsy 
evidence during weaning of recurrent hepatitis attributable 
to Non-A Non-B virus (later shown to be Hepatitis C). A 
third recipient whose original disease was biliary atresia, 
developed de novo C virus hepatitis infection. Weaning has 
continued in these patients with stabilization of liver injury 
tests. 
Recurrent Autoimmune Disease (II = 2). Two patients 
who were 7 and 8 years post-transplantation when they 
entered the study, were diagnosed with histopathologically 
obvious recurrent primary biliary cirrhosis 7 and 24 months 
after the initiation of weaning. Liver function tests normal-
ized after return to the preexisting CyA-based baseline 
immunosuppression. including prednisone. There has been 
no recurrence of autoimmune hepatitis in this series. 
Bile Duct Obstruction (II = 3). The liver function abnor-
malities in all 3 patients were incorrectly attributed to 
rejection and briefly treated as such in 2 cases. Liver 
enzyme values normalized in all 3 recipients after bile duct 
decompression and weaning was resumed. 
Previously Reported Equivocal Cases 
In our report 2 years ago of the first portion of the current 
prospective series. there were II) liver recipients whose 
reasons for enzyme elevations during weaning were not 
considered to he unconditionally estahlishedK~ In the inter-
L 
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vening 2 years, 10 of these patients have had progression of 
the suspected pathologic process (bolded patients, Table 2); 
5 have remained unchanged with continuation or comple-
tion of weaning, one died from pulmonary complication of 
cystic fibrosis and 3 were withdrawn from the protocol. 
DISCUSSION 
The rationale for post-transplant drug weaning rests with 
recent evidence suggesting that the leukocytes (including 
stem cells) contained in organs migrate after transplanta-
tion and produce persistent chimerism which is essential for 
sustained survival of the allografts. 1 We have emphasized 
that chimerism is not the same as tolerance. l .5 Chimerism 
and the derivative state of tolerance (if it is achieved) are 
almost contemporaneous in numerous rodent models of 
liver transplantation, many of which do not require immu-
nosuppression.6 In contrast, the cause (chimerism) and the 
effect (tolerance) are separated by months or years when 
liver transplantation is performed in outbred animals and 
humans no matter what the means of immunosuppression.7 
The duration of this critical period must be determined at 
present by trial and potential error. Although many liver 
recipients have stopped immunosuppression, the desired 
drug-free end-point may never be achieved in some patients 
whose chimerism (and organ allografts) can nevertheless be 
maintained for a lifetime under continuous immunosup-
pression. The error has been pointed outl.5•7 of believing 
that either the presence or the quantity of donor leukocyte 
chimerism can be used per se to guide decisions about drug 
weaning.8 - 1O 
The majority of the patients entered into the trial had 
been kept at a maintenance level of immunosuppression 
higher than was needed. Even those patients who devel-
oped rejection during the weaning process are receiving less 
average immunosuppression than when they started. The 
potential benefits of weaning are too obvious to enumerate. 
Consequently, our emphasis in this report has been on the 
incidence of rejection which was proved to have occurred 
acutely at some time during or after weaning in at least 18 
(19%) of the 95 patients entered. Seven more unverified 
cases were placed in ~he acute rejection category including 
3 in which biopsy only revealed minor duct injury. Including 
these 7 patients whose restoration of immunosuppression 
to preexisting levels resulted in a clinical response, there 
was a 25 of 95 (26%) incidence of acute rejection which 
occurred from 0.2 to 42 months after starting the weaning, 
and no unequivocal cxamples of chronic rejection. All but 3 
of the rejections were classed as minimal to mild. necessi-
tating only restoration of the previous baseline treatment. 
However. the rejection was histopathologically moderate or 
severe in the exceptional cases and I of these patients 
became jaundiced with a peak bilirubin of 12 mg',r. All 3 
were rescued with tacrolimus. 
The trial was not marred bv anv examples llf chronic 
rejection. at least tw the crit;ria ~onventionally lIsed to 
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make this diagnosis.l1 However, when 3 patients developed 
low grade de novo histopathologic findings of duct injury 
suggestive of incipient chronic rejection, immunosuppres-
sion was restored to preexisting levels (n = 2) or replaced 
with tacrolimus (n = 1). 
The practical lessons from this experience deserve strong 
emphasis. One is the absolute necessity of close physician 
surveillance with frequent assessments of liver function, 
repeat biopsy with the slightest suspicion of rejection. and 
prompt restoration of immunosuppression if this is the 
diagnosis (which it frequently is not). In addition, weaning 
should not be as abrupt as was done in the early patients of 
this series or in the trial of Sanborn et al.12 The risk of 
recurrent autoimmune disease was previously discussed in 
our earlier report,2 Although recurrence of autoimmune 
hepatitis has not yet been observed, 2 patients with PBC 
developed recurrence, raising the question whether at-
tempts to completely wean such patients should be made. 
With these provisos, our conclusion is that drug weaning 
is an important management consideration for a large 
number of stable, long-surviving liver recipients. Weaning 
apparently can be safely carried to completion in a signifi-
cant percentage of this population in which complications 
of immunosuppression have been the principal cause of late 
death.l However, the long term benefits of drug reduction 
or discontinuation need to be continually measured and 
balanced against the risk of drug withdrawal. The risk can 
be minimized by careful management and timely interven-
tion when called for. Finally, the experience in this study 
has emphasized the frequency with which late hepatic 
allograft dysfunction is due to causes other than rejection. !3 
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